BACKGROUND: We created a standardized model of severe Staphylococcus aureus endophthalmitis in the aphakic rabbit eye to test various treatment strategies involving corticosteroid administration in addition to vitrectomy and antibiotic treatment. MATERIALS AND METHODS: In 71 aphakic New Zealand albino rabbit eyes, experimental endophthalmitis was created by injecting 10(5) colony-forming units of Staphylococcal aureus. The animals were divided into 5 groups. One control group was followed up without treatment, while 4 groups were treated with vitrectomy and intraocular cefazolin injection. Two groups were also treated with intramuscular methylprednisolone, 1 group beginning on the day of surgery and 1 group beginning on the following day. In the final group, dexamethasone, 400 micrograms, was injected into the vitreous cavity at the close of surgery. Culture results were compared on the first 2 days after surgery. Inflammatory scores, including development of total corneal opacity, were assessed over a 21-day follow-up period, and histopathologic grading was carried out at the conclusion of the clinical observations. RESULTS: Simultaneous administration of systemic corticosteroids beginning on the day of vitrectomy decreased inflammatory scores 1 week after institution of therapy but did not affect final scores. Delay of initiation of intramuscular corticosteroid until the first postoperative day negated the positive effects. Administration of intraocular corticosteroids was associated with an increase in inflammatory scores throughout the period of observation, an increase in percentage of eyes that developed opaque corneas, an increase in choroidal inflammation graded moderate or severe, and an increase in retinal necrosis compared with vitrectomy and cefazolin injection alone. CONCLUSIONS: This data suggest caution in the use of intraocular corticosteroids in treatment of severe endophthalmitis.
BACKGROUND: We created a standardized model of severe Staphylococcus aureus endophthalmitis in the aphakic rabbit eye to test various treatment strategies involving corticosteroid administration in addition to vitrectomy and antibiotic treatment. MATERIALS AND METHODS: In 71 aphakic New Zealand albino rabbit eyes, experimental endophthalmitis was created by injecting 10(5) colony-forming units of Staphylococcal aureus. The animals were divided into 5 groups. One control group was followed up without treatment, while 4 groups were treated with vitrectomy and intraocular cefazolin injection. Two groups were also treated with intramuscular methylprednisolone, 1 group beginning on the day of surgery and 1 group beginning on the following day. In the final group, dexamethasone, 400 micrograms, was injected into the vitreous cavity at the close of surgery. Culture results were compared on the first 2 days after surgery. Inflammatory scores, including development of total corneal opacity, were assessed over a 21-day follow-up period, and histopathologic grading was carried out at the conclusion of the clinical observations. RESULTS: Simultaneous administration of systemic corticosteroids beginning on the day of vitrectomy decreased inflammatory scores 1 week after institution of therapy but did not affect final scores. Delay of initiation of intramuscular corticosteroid until the first postoperative day negated the positive effects. Administration of intraocular corticosteroids was associated with an increase in inflammatory scores throughout the period of observation, an increase in percentage of eyes that developed opaque corneas, an increase in choroidal inflammation graded moderate or severe, and an increase in retinal necrosis compared with vitrectomy and cefazolin injection alone. CONCLUSIONS: This data suggest caution in the use of intraocular corticosteroids in treatment of severe endophthalmitis.
Authors: M H Lebel; B J Freij; G A Syrogiannopoulos; D F Chrane; M J Hoyt; S M Stewart; B D Kennard; K D Olsen; G H McCracken Journal: N Engl J Med Date: 1988-10-13 Impact factor: 91.245
Authors: C M Odio; I Faingezicht; M Paris; M Nassar; A Baltodano; J Rogers; X Sáez-Llorens; K D Olsen; G H McCracken Journal: N Engl J Med Date: 1991-05-30 Impact factor: 91.245
Authors: Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan Journal: Prog Retin Eye Res Date: 2016-05-03 Impact factor: 21.198
Authors: Ivan M Gan; Luana C Ugahary; Jaap T van Dissel; Jan C van Meurs Journal: Graefes Arch Clin Exp Ophthalmol Date: 2005-05-20 Impact factor: 3.117
Authors: Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore Journal: Clin Microbiol Rev Date: 2002-01 Impact factor: 26.132
Authors: Brandt J Wiskur; Michael L Robinson; Allison J Farrand; Billy D Novosad; Michelle C Callegan Journal: Invest Ophthalmol Vis Sci Date: 2008-04 Impact factor: 4.799
Authors: Eric W Lindstedt; Carlien A Bennebroek; Dymph J van der Werf; Marc Veckeneer; Annette Ossewaarde-van Norel; Chris C Mayland Nielsen; Rene J Wubbels; Jaap T van Dissel; Jan C van Meurs Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-08-10 Impact factor: 3.117
Authors: Salai Madhumathi Parkunan; C Blake Randall; Roger A Astley; Glaucia C Furtado; Sergio A Lira; Michelle C Callegan Journal: J Leukoc Biol Date: 2016-06-10 Impact factor: 4.962